Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$5.37 ▲ +0.23
(+4.56%)
MKT CAP: $13.5M • VOL: 238.7K
52W L $4 52W H $44
ROARABLE / RQD
D • 44/100
PIOTROSKI
2 / 9
ATYR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $190.0K | $235.0K | $353.0K |
| YoY Revenue Growth % | -19.1% | -33.4% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$77.6M | -$67.9M | -$54.9M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$74.1M | -$64.0M | -$50.4M |
| EBITDA (Normalized) | -$77.6M | -$67.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$62.0M | -$69.1M | -$33.2M |
| Capital Expenditures (CapEx) | $77.0K | $65.0K | — |
| Free Cash Flow (FCF) | -$62.1M | -$69.2M | -$33.2M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $10.7M | $11.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $67.5M | $70.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ATYR.